Zacks Investment Research cut shares of Axcella Health (NASDAQ:AXLA) from a hold rating to a sell rating in a report released on Friday morning, Zacks.com reports.

According to Zacks, “Axcella Health Inc. is a biotechnology company. It is engaged in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism. The company’s principal candidate consists of AXA1665, AXA1125, AXA1957, AXA2678 and AXA4010 which are in clinical stage. Axcella Health Inc. is based in Cambridge, Massachusetts. “

Other equities research analysts have also issued reports about the company. Svb Leerink started coverage on Axcella Health in a research report on Monday, June 3rd. They set an outperform rating and a $21.00 price objective for the company. Goldman Sachs Group began coverage on Axcella Health in a report on Sunday, June 2nd. They set a buy rating and a $25.00 price target for the company. JPMorgan Chase & Co. began coverage on Axcella Health in a report on Monday, June 3rd. They set an overweight rating and a $20.00 price target for the company. Finally, Leerink Swann began coverage on Axcella Health in a report on Monday, June 3rd. They set an outperform rating for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Axcella Health presently has a consensus rating of Buy and a consensus target price of $22.00.

Shares of NASDAQ AXLA opened at $7.94 on Friday. Axcella Health has a one year low of $6.10 and a one year high of $15.99. The company has a debt-to-equity ratio of 0.27, a current ratio of 17.42 and a quick ratio of 11.03. The business’s 50-day simple moving average is $7.97.

Axcella Health (NASDAQ:AXLA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.95) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.31). Equities analysts expect that Axcella Health will post -3.14 EPS for the current year.

In other news, Director David R. Epstein purchased 4,556 shares of Axcella Health stock in a transaction dated Wednesday, July 3rd. The stock was acquired at an average cost of $8.76 per share, for a total transaction of $39,910.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David R. Epstein purchased 5,500 shares of Axcella Health stock in a transaction dated Friday, June 28th. The shares were purchased at an average price of $10.02 per share, with a total value of $55,110.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 38,293 shares of company stock valued at $337,682.

Several institutional investors have recently made changes to their positions in the company. Morgan Stanley acquired a new stake in shares of Axcella Health during the 2nd quarter valued at about $56,000. Northern Trust Corp acquired a new stake in shares of Axcella Health during the 2nd quarter valued at about $90,000. KCL Capital L.P. acquired a new stake in shares of Axcella Health during the 2nd quarter valued at about $93,000. Tower Research Capital LLC TRC acquired a new stake in shares of Axcella Health during the 2nd quarter valued at about $122,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Axcella Health during the 2nd quarter valued at about $499,000. Institutional investors and hedge funds own 54.90% of the company’s stock.

Axcella Health Company Profile

There is no company description available for Axcella Health Inc

Further Reading: How is a price target determined?

Get a free copy of the Zacks research report on Axcella Health (AXLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.